Cagent Vascular develops a serration technology for improving the treatment of cardiovascular disease.
Cagent Vascular has raised $41.0M in total funding. The most recent round was Series D. The last funding was announced in May 2026.
Cagent Vascular's investors include U.S. Venture Partners, Trinity Capital, Ben Franklin Technology Partners of Southeastern Pennsylvania, Ben Franklin Technology Partners, Astoria Health Investors.
Cagent Vascular is headquartered in Wayne, United States.
Cagent Vascular develops a serration technology for improving the treatment of cardiovascular disease.
Cagent Vascular is at the Series D stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cagent Vascular — Funding & Investors." VCBacked, May 19, 2026, https://www.vcbacked.co/company/cagent-vascular. Accessed October 30, 2026.
VCBacked. (2026). Cagent Vascular — Funding & Investors. Retrieved October 30, 2026, from https://www.vcbacked.co/company/cagent-vascular
{{cite web |title=Cagent Vascular — Funding & Investors |url=https://www.vcbacked.co/company/cagent-vascular |website=VCBacked |access-date=October 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated